The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2020

Filed:

Apr. 27, 2018
Applicants:

Samsung Life Public Welfare Foundation, Seoul, KR;

Pangen Biotech Inc., Gyeonggi-Do, KR;

Inventors:

Do Hyun Nam, Seoul, KR;

Yong Jae Shin, Gyeonggi-do, KR;

Jae Hyun Lee, Gyeonggi-Do, KR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C12N 15/70 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 15/70 (2013.01); A61K 38/1764 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/47 (2013.01); C07K 16/2803 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.


Find Patent Forward Citations

Loading…